Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Veracyte Inc (NASDAQ: VCYT) closed at $39.07 down -1.16% from its previous closing price of $39.53. In other words, the price has decreased by -$1.16 from its previous closing price. On the day, 0.61 million shares were traded. VCYT stock price reached its highest trading level at $39.825 during the session, while it also had its lowest trading level at $38.73.
Ratios:
For a deeper understanding of Veracyte Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 53.61. For the most recent quarter (mrq), Quick Ratio is recorded 4.79 and its Current Ratio is at 5.08. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on December 05, 2024, Downgraded its rating to Neutral and sets its target price to $37 from $38 previously.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $50.
On October 16, 2024, UBS started tracking the stock assigning a Buy rating and target price of $43.UBS initiated its Buy rating on October 16, 2024, with a $43 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 13 ’24 when Stapley Marc sold 5,590 shares for $43.42 per share. The transaction valued at 242,737 led to the insider holds 307,345 shares of the business.
MARC STAPLEY bought 5,590 shares of VCYT for $248,196 on Dec 13 ’24. On Dec 04 ’24, another insider, Febbo Phillip G., who serves as the Chief Scientific & Med Officer of the company, sold 3,934 shares for $44.09 each. As a result, the insider received 173,447 and left with 82,414 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 3027909376 and an Enterprise Value of 2773625600. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.12 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 6.521 whereas that against EBITDA is 63.017.
Stock Price History:
Over the past 52 weeks, VCYT has reached a high of $46.00, while it has fallen to a 52-week low of $18.61. The 50-Day Moving Average of the stock is 2.41%, while the 200-Day Moving Average is calculated to be 39.21%.
Shares Statistics:
For the past three months, VCYT has traded an average of 782.72K shares per day and 728480 over the past ten days. A total of 77.49M shares are outstanding, with a floating share count of 76.39M. Insiders hold about 1.43% of the company’s shares, while institutions hold 106.24% stake in the company. Shares short for VCYT as of 1732838400 were 2966704 with a Short Ratio of 3.79, compared to 1730332800 on 3101931. Therefore, it implies a Short% of Shares Outstanding of 2966704 and a Short% of Float of 4.2700000000000005.
